pLKO.1 shMTH1-2 Citations (2)
Originally described in: Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence.Rai P, Onder TT, Young JJ, McFaline JL, Pang B, Dedon PC, Weinberg RA Proc Natl Acad Sci U S A. 2009 Jan 6. 106(1):169-74. PubMed Journal
Articles Citing pLKO.1 shMTH1-2
Articles |
---|
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Stromberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G. Nature. 2014 Apr 10;508(7495):222-7. doi: 10.1038/nature13194. Epub 2014 Apr 2. PubMed |
TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. Moukengue B, Brown HK, Charrier C, Battaglia S, Baud'huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F. EBioMedicine. 2020 Mar;53:102704. doi: 10.1016/j.ebiom.2020.102704. Epub 2020 Mar 7. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.